Per-patient trial cost of orphan drugs against non-orphan drugs, Phase 3 (EvaluatePharma data)

2.5:1

ratio of per-patient cost, orphan to non-orphan, US

“These estimates resulted in a ratio of per patient costs for orphan: non-orphan of 2.5:1.”

Jayasundara et al., Orphanet Journal of Rare Diseases 2019, Estimating the clinical cost of drug development for orphan versus non-orphan drugs, 2019-01

Kind of source

Peer-reviewed study

Read on

2026-11-06

Daily check

Quote found at the source on 2026-11-06

What to know

Measures what a patient costs a trial sponsor, which is the cost a contributed rare-disease record can replace; the authors applied the same ratio to Phase 2 and note the data are limited.